respons
next
gener
vaccin
includ
viruslik
particl
vlp
noninfecti
immunogen
act
carrier
link
peptideantigen
next
gener
vaccin
also
includ
dna
vaccin
transfect
cell
order
express
antigen
interest
deliv
either
plasmid
form
vector
use
intact
bacteria
viru
safeti
concern
tradit
next
gener
vaccin
includ
potenti
induc
local
system
reaction
local
reaction
often
observ
vaccin
administ
via
intramuscular
subcutan
rout
administr
concern
sever
pain
red
swell
addit
format
granuloma
abcess
inject
site
necrosi
region
lymphadenopathi
vaccin
might
induc
system
reaction
includ
nausea
diarrhea
gener
malais
potenti
sever
respons
might
includ
anaphylaxi
pyrogen
fever
respons
organ
speci
fi
c
toxic
immunemedi
toxic
cytokin
releas
immun
activ
suppress
autoimmun
diseas
potenti
concern
includ
effect
reproduct
develop
carcinogen
live
attenu
pathogenbas
vaccin
risk
revers
virul
addit
concern
regard
administr
vaccin
subject
impair
immun
system
next
gener
vaccin
includ
adjuv
potenti
synergi
interact
mechan
action
vaccin
antigen
adjuv
adjuv
typic
act
enhanc
immun
respons
might
caus
excess
amount
proin
fl
ammatori
pyrogen
mediat
lead
exacerb
local
system
effect
next
gener
vaccin
dnabas
vector
speci
fi
c
risk
recombin
integr
host
genom
therefor
biodistribut
integr
persist
dna
vector
import
evalu
dnabas
vector
vaccin
prior
start
clinic
studi
next
gener
vaccin
adequ
inform
pharmacolog
toxicolog
effect
vaccin
avail
includ
vitro
vivo
studi
examin
mechan
action
potenti
ef
fi
caci
vaccin
addit
thorough
evalu
safeti
vaccin
chapter
focu
nonclin
safeti
assess
vaccin
includ
discuss
toxicolog
studi
need
perform
new
vaccin
clinic
develop
qualiti
control
test
need
demonstr
vaccin
product
safe
use
human
nonclin
test
tradit
vaccin
focus
mainli
ef
fi
caci
studi
anim
safeti
pass
vaccin
formul
time
extent
nonclin
safeti
test
greatli
increas
requir
full
toxicolog
studi
vaccin
candid
implement
accord
current
guidelin
tabl
present
nonclin
safeti
studi
vaccin
candid
includ
next
gener
vaccin
align
overal
principl
jj
wolf
et
al
therapeut
cancer
vaccin
fda
draft
guidanc
industri
clinic
consider
therapeut
cancer
vaccin
cell
substrat
viral
vaccin
fda
character
quali
fi
cation
cell
substrat
biolog
materi
use
product
viral
vaccin
infecti
diseas
indic
recommend
evalu
anim
cell
cultur
substrat
manufactur
biolog
medicin
product
character
cell
bank
ich
viral
safeti
evalu
biotechnolog
product
deriv
cell
line
human
anim
origin
strategi
nonclin
safeti
assess
vaccin
toxicolog
evalu
detect
potenti
local
system
toxic
time
guidelin
allow
appropri
fl
exibl
studi
design
accord
type
vaccin
candid
human
popul
treat
dose
regimen
appli
clinic
use
purpos
nonclin
toxicolog
evalu
examin
toxic
compon
present
vaccin
formul
addit
toxic
induc
immun
respons
toxicolog
studi
provid
inform
might
help
determin
safe
start
dose
clinic
studi
identifi
potenti
toxic
target
organ
note
limit
safeti
evalu
anim
sinc
effect
anim
alway
indic
effect
might
seen
human
rare
toxic
appear
certain
subpopul
detect
clinic
studi
nevertheless
toxicolog
studi
provid
import
safeti
data
vaccin
develop
toxicolog
program
vaccin
vari
depend
type
vaccin
intend
use
human
overview
main
toxicolog
studi
type
provid
tabl
gener
vaccin
need
evalu
repeatdos
toxicolog
studi
prior
start
phase
clinic
studi
development
reproduct
toxicolog
studi
need
vaccin
administ
women
childbear
potenti
perform
parallel
phase
clinic
studi
biodistribut
studi
need
dnabas
viralvector
vaccin
toxicolog
studi
perform
anim
need
perform
complianc
nation
intern
law
protect
laboratori
anim
toxicolog
studi
protocol
review
approv
institut
anim
care
use
committe
iacuc
toxicolog
studi
usual
conduct
complianc
good
laboratori
practic
glp
vaccin
lot
use
glp
studi
lot
manufactur
similar
product
process
formul
releas
speci
fi
cation
lot
intend
clinic
use
stabil
data
need
support
use
vaccin
durat
toxicolog
studi
repeatdos
toxic
studi
gener
need
vaccin
type
singl
speci
typic
use
evalu
must
shown
relev
speci
base
immunogen
ef
fi
caci
vaccin
select
speci
mani
case
rodent
rabbit
use
toxicolog
evalu
nonhuman
primat
use
relev
speci
exist
diseas
model
typic
use
toxicolog
studi
supplementari
studi
diseas
model
could
use
address
speci
fi
c
toxicolog
concern
exampl
transgen
mous
model
alzheim
diseas
overexpress
human
b
amyloid
protein
could
use
demonstr
alzheim
diseas
vaccin
candid
caus
meningoenceph
microhemorrhag
brain
repeatdos
toxic
studi
rout
administr
clinic
rout
use
anim
howev
intens
dose
regimen
appli
anim
compar
plan
regimen
human
overdos
approach
base
number
dose
administ
ie
one
dose
administ
anim
compar
number
dose
administ
human
greater
dose
frequenc
ie
everi
week
anim
compar
typic
everi
month
human
driven
intent
maxim
potenti
hazard
identi
fi
cation
nonclin
safeti
studi
addit
fullhuman
dose
vaccin
maximum
amount
inject
select
anim
speci
also
result
much
higher
exposur
vaccin
anim
base
smaller
bodi
weight
compar
human
importantli
vaccin
formul
use
toxicolog
studi
repres
propos
clinic
formul
therefor
adjuv
vaccin
vaccin
antigen
adjuv
test
togeth
base
evid
immun
respons
adjuv
vaccin
evalu
within
con
fi
ne
immunogen
vaccin
antigen
control
group
includ
repeatdos
toxic
studi
includ
adjuv
alon
applic
salinetr
group
group
size
vari
depend
anim
speci
use
rodent
per
gender
per
group
usual
includ
necropsi
nonrod
number
per
group
typic
per
gender
per
group
necropsi
antemortem
paramet
evalu
includ
strategi
nonclin
safeti
assess
vaccin
daili
clinic
observ
weekli
bodi
weight
food
consumpt
physic
examin
assess
local
reactogen
perform
vaccin
dose
administ
speci
fi
c
safeti
pharmacolog
evalu
eg
bodi
temperatur
electrocardiogram
central
nervou
system
evalu
could
incorpor
within
repeatdos
toxic
studi
vaccin
administ
intramuscularli
particular
attent
focus
red
swell
inject
site
impair
limb
use
inject
clinic
chemistri
urinalys
hematolog
serum
biochemistri
coagul
evalu
typic
perform
day
fi
rst
vaccin
schedul
necropsi
immunogen
assess
perform
end
studi
describ
sect
ophthalm
examin
includ
fi
rst
vaccin
prior
fi
rst
necropsi
necropsi
perform
two
occas
day
last
dose
administ
treatmentfre
period
week
determin
whether
effect
detect
fi
rst
necropsi
start
recov
time
postmortem
evalu
includ
gross
examin
major
organ
organ
weight
select
organ
histopatholog
evalu
standard
list
tissu
treatmentrel
effect
typic
observ
repeatdos
studi
vaccin
administ
parenter
includ
fl
ammat
inject
site
hyperplasia
drain
lymph
node
increas
spleen
weight
clinic
chemistri
chang
indic
fl
ammatori
respons
typic
sever
transient
chang
therefor
consid
advers
effect
gener
approach
toxicolog
evalu
therapeut
prophylact
vaccin
similar
howev
small
differ
repeatdos
toxic
studi
design
exampl
therapeut
vaccin
interv
dose
administr
anim
would
follow
clinic
studi
design
close
includ
total
number
dose
dose
interv
wherea
prophylact
vaccin
dose
interv
could
condens
anim
eg
clinic
dose
frequenc
could
condens
toxicolog
studi
one
dose
administ
anim
compar
number
dose
clinic
regimen
percept
potenti
differ
toler
advers
effect
therapeut
vaccin
compar
prophylact
vaccin
sinc
therapeut
vaccin
address
lifethreaten
condit
might
treatment
option
howev
bene
fi
ttorisk
ratio
need
care
evalu
depend
target
popul
note
certain
target
popul
therapeut
vaccin
might
immunosuppress
due
concomit
medic
therefor
caution
need
evalu
bene
fi
ttorisk
ratio
therapeut
prophylact
vaccin
novel
adjuv
incorpor
next
gener
vaccin
formul
order
reduc
amount
vaccin
antigen
increas
magnitud
durat
immun
respons
therebi
reduc
frequenc
booster
immun
need
adjuv
use
modifi
desir
immun
respons
activ
innat
adapt
arm
immun
system
novel
adjuv
test
clinic
trial
current
includ
miner
salt
eg
aluminum
hydroxid
oil
emuls
eg
particul
adjuv
eg
virosom
iscom
microbi
deriv
eg
monophosphoryl
lipid
endogen
immunomodul
eg
human
gmcsf
adjuv
develop
past
eg
freund
adjuv
found
accept
larg
scale
vaccin
campaign
due
safeti
concern
includ
sever
local
reaction
acut
toxic
delay
hypersensit
ema
committe
medicin
product
issu
guidelin
adjuv
vaccin
human
use
cover
nonclin
clinic
aspect
consider
safeti
pro
fi
le
adjuv
alon
would
typic
impact
posit
neg
interact
vaccin
antigen
need
evalu
context
full
vaccin
formul
theoret
concern
increas
toxic
due
synergi
adjuvantinduc
respons
vaccineinduc
respons
rais
regulatori
author
propos
toxicolog
character
chemicalbas
adjuv
manner
similar
new
chemic
entiti
nce
desir
order
understand
uniqu
toxic
pro
fi
le
adjuv
speciesspeci
fi
c
test
two
speci
one
rodent
one
nonrod
adjuv
speciesspeci
fi
c
test
one
speci
might
justi
fi
ed
new
adjuv
typic
assess
local
toler
system
toxic
repeatdos
toxic
studi
repeatdos
toxic
studi
design
could
fl
ect
propos
clinic
use
vaccin
number
administr
anim
higher
number
plan
human
gener
dose
rang
toxicolog
studi
need
perform
adjuv
alon
dose
test
would
fl
ect
target
clinic
use
typic
much
lower
maximum
toler
dose
purpos
toxicolog
studi
adjuv
alon
establish
margin
safeti
rather
maximum
toler
dose
full
necropsi
histopatholog
includ
repeatdos
toxic
studi
similar
nce
assess
genotox
potenti
novel
chemic
adjuv
also
recommend
use
standard
batteri
test
eg
potenti
gene
mutat
chromosom
aberr
primari
dna
damag
carcinogen
studi
requir
adjuv
sinc
use
time
low
dose
evalu
adjuv
effect
reproduct
toxic
need
inclus
adjuv
vaccin
administ
women
childbear
potenti
pregnanc
strategi
nonclin
safeti
assess
vaccin
although
valu
studi
adjuv
alon
risk
assess
vaccin
whole
still
debat
light
guidelin
anticip
rigor
comprehens
toxicolog
program
novel
adjuv
alon
requir
futur
perhap
practic
approach
complianc
expect
develop
vaccin
contain
novel
adjuv
could
includ
gener
master
file
given
adjuv
approach
nonclin
safeti
studi
adjuv
alon
would
includ
master
file
potenti
repetit
safeti
studi
adjuv
alon
could
omit
differ
deliveri
system
use
incorpor
immunopotenti
focu
immun
respons
desir
path
sever
type
deliveri
devic
vaccin
also
evalu
order
ef
fi
cientli
target
vaccin
speci
fi
c
area
bodi
reduc
pain
associ
needlebas
inject
deliveri
system
includ
emuls
eg
microparticl
eg
liposom
biodegrad
polyest
might
immunostimulatori
capabl
type
deliveri
system
encapsul
protect
antigen
degrad
act
vehicl
mimic
structur
natur
lipid
bilay
membran
allow
enter
reticuloendotheli
system
endocytosi
deliveri
system
could
also
stabil
antigen
result
formul
thermost
deliveri
system
present
vaccin
formul
need
includ
formul
use
toxicolog
studi
anim
group
anim
dose
deliveri
system
eg
lipsom
emuls
could
includ
toxicolog
studi
compar
effect
deliveri
system
combin
vaccin
antigen
deliveri
devic
use
target
vaccin
antigen
proper
locat
bodi
includ
less
pain
way
deliv
vaccin
antigen
parenter
microneedl
patch
autoinjector
oral
intranas
vaccin
also
develop
order
less
invas
method
administ
vaccin
toxicolog
studi
vaccin
intend
deliveri
clinic
use
speci
fi
c
devic
includ
use
clinic
deliveri
devic
anim
studi
particularli
import
new
type
inject
devic
sinc
local
irrit
concern
devic
alreadi
clear
use
human
crossrefer
investig
devic
exempt
master
file
could
list
investig
new
drug
applic
vaccin
manufactur
devic
usual
perform
biocompat
test
evalu
interact
devic
tissu
biocompat
studi
util
analyt
chemistri
vitro
test
anim
model
speci
fi
c
type
test
might
perform
devic
includ
cytotox
tissu
cultur
sensit
assay
irrit
test
acut
system
toxic
test
intracutan
test
implant
test
hemocompat
test
dnabas
vaccin
electropor
use
deliv
dna
cell
toxic
studi
examin
speci
fi
c
method
electropor
need
electropermeabil
may
leav
target
tissu
damag
depend
upon
electr
paramet
associ
electropor
techniqu
clinic
accept
use
genedna
deliveri
perman
damag
skin
electropor
devic
intend
administr
might
need
adjust
use
anim
exampl
needl
length
inject
array
could
differ
anim
human
studi
excipi
buffer
compon
preserv
ad
vaccin
formul
improv
stabil
vaccin
compon
select
excipi
inclus
vaccin
formul
prefer
use
excipi
toxicolog
data
avail
previous
use
market
vaccin
product
clinic
safeti
alreadi
demonstr
excipi
regard
novel
scienti
fi
c
review
avail
toxicolog
data
would
provid
suf
fi
cient
toxicolog
evalu
excipi
novel
excipi
toxicolog
studi
requir
studi
excipi
within
repeatdos
toxic
studi
vaccin
relev
respect
interact
excipi
vaccin
formul
compon
residu
contamin
substanc
use
manufactur
process
may
present
fi
nal
formul
residu
amount
eg
formaldehyd
toxin
viral
growth
media
speci
fi
c
regulatori
guidelin
avail
safeti
assess
vaccin
residu
contamin
determin
estim
worst
case
mass
residu
contamin
per
vaccin
dose
could
made
measur
directli
assay
exist
ich
guidelin
impur
ich
cover
biolog
biotechnolog
product
howev
gener
principl
guidelin
could
appli
exampl
ich
state
drug
administ
g
per
day
maximum
report
threshold
impur
degrad
ich
residu
solvent
discuss
approach
establish
permit
daili
exposur
pde
limit
concept
might
consid
applic
residu
contamin
vaccin
threshold
toxicolog
concern
ttc
concept
develop
risk
assess
human
exposur
even
harm
chemic
could
appli
excipi
residu
vaccin
goal
establish
applic
accept
ttc
valu
avoid
unnecessari
toxic
test
safeti
evalu
human
intak
threshold
amount
would
safe
even
harm
chemic
develop
ttc
concept
expert
group
intern
life
scienc
institut
ilsi
consid
wide
rang
toxicolog
concern
includ
metabol
accumul
structur
alert
strategi
nonclin
safeti
assess
vaccin
endocrin
disrupt
chemic
genet
toxic
carcinogen
neurotox
teratogen
development
toxic
allergen
immunotox
publish
work
adopt
european
medicin
agenc
establish
guidelin
limit
genotox
impur
pharmaceut
develop
although
impur
guidelin
address
ttc
level
potent
genotox
carcinogen
intend
appli
residu
contamin
could
approach
taken
address
level
residu
contamin
vaccin
anim
speci
use
nonclin
safeti
studi
vaccin
candid
abl
mount
immun
respons
exampl
antibodi
level
vaccin
antigen
time
toxicolog
studi
expect
conduct
laboratori
anim
speci
histor
control
data
exist
help
distinguish
true
toxic
caus
test
vaccin
potenti
background
test
articletreat
relat
lesion
occasion
found
thorough
histopatholog
examin
organ
tissu
involv
studi
rat
commonli
use
toxicolog
studi
broad
rang
chemic
entiti
typic
speci
choic
toxic
studi
vaccin
candid
howev
rat
rare
use
nonclin
pharmacolog
studi
focus
protect
therapeut
immun
respons
vaccin
candid
instead
mice
rabbit
andor
nonhuman
primat
nhp
typic
speci
vaccin
pharmacolog
studi
base
avail
model
diseas
attempt
predict
immun
respons
anim
human
order
bridg
toxicolog
pharmacolog
anim
speci
measur
immun
respons
speci
select
nonclin
safeti
evalu
eg
rat
vaccin
candid
includ
separ
studi
within
repeatdos
toxic
studi
approach
provid
indirect
evid
exposur
activ
vaccin
align
gener
principl
toxicolog
studi
demonstr
anim
exposur
test
articl
follow
administr
test
articl
cours
studi
requir
howev
base
recent
discuss
regulatori
guidelin
addit
expect
requir
toxicolog
studi
vaccin
anim
speci
sensit
pathogen
organ
toxin
target
vaccineinduc
immun
respons
address
expect
toxicolog
studi
may
problemat
diseasesensit
speci
differ
routin
speci
former
well
character
provid
reliabl
data
distinguish
background
lesion
rel
may
consid
vaccinerel
effect
typic
solut
problem
would
involv
use
one
speci
evalu
safeti
vaccin
candid
exampl
use
routin
speci
wellcontrol
toxic
studi
ie
compliant
good
laboratori
practic
regul
nonroutin
speci
exploratori
safeti
studi
like
less
comprehens
endpoint
focus
pathogenspeci
fi
c
concern
type
studi
immun
respons
vaccin
demonstr
evalu
immun
respons
vaccin
reli
immunoassay
develop
order
measur
relev
endpoint
ie
antibodi
respons
cellular
immun
respons
measur
speci
fi
c
antibodi
standard
elisa
format
multiplex
assay
multipl
antigen
vaccin
candid
often
appli
candid
vaccin
target
cellular
arm
immun
respons
assay
measur
cytokinesecret
antigenspeci
fi
c
lymphocyt
g
interferon
elispot
util
assay
typic
develop
perform
support
nonclin
pharmacolog
studi
eg
use
mice
rabbit
nhp
adopt
use
toxicolog
select
speci
eg
rat
immun
stimul
intend
pharmacolog
effect
vaccin
thu
effect
variou
immun
system
paramet
expect
desir
effect
may
includ
chang
hematolog
variou
white
blood
cell
type
serum
biochemistri
eg
protein
globulin
paramet
local
irrit
fl
ammat
inject
site
lymphoid
enlarg
hyperplasia
spleen
weight
increas
effect
gener
modest
revers
consequ
intend
pharmacolog
activ
vaccin
usual
consid
advers
tradit
vaccin
contain
aluminum
salt
adjuv
predominantli
function
via
local
rather
system
mechan
system
fl
ammatori
respons
vaccin
gener
concern
howev
indic
theoret
concern
synergist
immun
stimul
seem
heighten
novel
particularli
molecular
adjuv
tolllik
receptor
tlr
agonist
cytokin
safeti
concern
use
immunostimulatori
adjuv
includ
potenti
excess
proin
fl
ammatori
pyrogen
respons
tnf
b
stronger
unexpect
organ
speci
fi
c
toxic
local
fl
ammat
cell
death
immunodysregul
sever
local
reactogen
increas
vascular
permeabl
cellular
fi
ltration
fl
uid
accumul
breakdown
self
toler
dysregul
cell
host
cell
therefor
potenti
system
fl
ammatori
respons
vaccin
particularli
contain
strategi
nonclin
safeti
assess
vaccin
immunoact
adjuv
expect
assess
within
nonclin
toxicolog
studi
sever
exampl
anim
safeti
studi
conduct
novel
adjuv
alon
includ
control
group
toxicolog
studi
vaccin
contain
adjuv
includ
oligonucleotid
eg
cpg
dna
sequenc
oil
emuls
eg
saponinbas
eg
adjuv
gener
con
fi
rmed
expect
dosedepend
effect
base
mechan
action
reveal
fi
nding
toxicolog
concern
contrast
exampl
unwant
immun
respons
patient
treat
experiment
therapeut
vaccin
clinic
trial
one
exampl
advers
cellmedi
toxic
induc
therapeut
vaccin
involv
amyloidb
vaccin
consist
b
amyloid
antigen
adjuv
use
clinic
studi
treatment
alzheim
diseas
symptom
meningoenceph
observ
trial
patient
predict
nonclin
safeti
studi
caus
unwant
immun
respons
dif
fi
cult
establish
base
retrospect
nonclin
studi
use
transgen
mous
model
diseas
suggest
inclus
adjuv
vaccin
might
contribut
advers
respons
involv
signi
fi
cant
ifng
tnfa
express
exampl
illustr
great
challeng
current
face
develop
safeti
evalu
vaccin
candid
regard
abil
prospect
identifi
potenti
overt
immun
stimul
presenc
desir
immun
respons
vaccin
great
effort
put
place
vaccin
develop
identi
fi
cation
biomark
advers
immun
stimul
nonclin
studi
recent
review
extens
studi
saponinbas
adjuv
fl
ect
line
work
progress
made
character
physicochem
properti
biolog
activ
well
marker
immun
respons
induc
novel
adjuv
describ
work
exploratori
assess
serum
marker
autoimmun
fl
ammat
allergi
base
clinic
studi
hcv
core
vaccin
contain
studi
measur
anticardiolipin
antibodi
glycoprotein
ige
level
evalu
result
necessarili
conclus
stage
help
direct
futur
work
biomark
anim
clinic
studi
anoth
line
current
research
potenti
biomark
immun
stimul
fl
ammat
includ
genet
pro
fi
ling
respons
adjuv
vaccin
metageneand
pathwaybas
analyt
approach
adopt
provid
quantit
readout
biolog
relev
use
studi
mode
action
rank
vaccin
adjuv
candid
develop
gene
pro
fi
ling
perform
peripher
blood
monkey
treat
sever
vaccin
known
clinic
advers
effect
gene
modul
data
analysi
approach
use
demonstr
one
gene
modul
could
use
classi
fi
er
predict
vaccineadjuv
reactogen
classi
fi
er
gene
set
appli
subsequ
monkey
studi
predict
reactogen
associ
experiment
vaccin
work
focus
establish
reliabl
biomark
appli
nonclin
clinic
safeti
evalu
ongo
step
address
concern
undesir
immun
stimul
toxicolog
studi
put
place
includ
addit
paramet
routin
measur
studi
exampl
potenti
prolong
system
fl
ammatori
respons
assess
measur
acut
phase
protein
eg
creactiv
protein
crp
level
complement
compon
andor
coagul
factor
part
enhanc
clinic
chemistri
analysi
serum
andor
plasma
sampl
collect
vaccin
anim
appropri
time
administr
vaccin
use
immun
potenti
adjuv
develop
antidna
antirna
antibodi
could
monitor
potenti
pathogen
autoimmun
respons
particular
tissu
could
evalu
target
immunohistochemistri
evalu
tissu
date
document
evid
reproduct
toxic
effect
human
caus
approv
vaccin
howev
regulatori
author
presum
product
safe
directli
test
use
appropri
preclin
test
method
welldesign
adequ
power
clinic
trial
therefor
address
potenti
development
hazard
vaccin
candid
development
toxic
studi
anim
model
current
requir
vaccin
indic
matern
immun
andor
immun
women
childbear
age
accord
fda
guidelin
titl
consider
reproduct
toxic
studi
prevent
vaccin
infecti
diseas
indic
development
reproduct
toxic
dart
studi
provid
inform
potenti
effect
vaccin
fertil
fetal
develop
postnat
develop
offspr
sinc
primari
concern
prevent
therapeut
vaccin
safeti
develop
growth
embryo
fetu
evalu
focus
effect
pregnantlact
femal
embryofet
develop
follow
exposur
femal
vaccin
implant
end
pregnanc
followup
offspr
wean
postnat
followup
pup
birth
wean
also
includ
assess
normal
growth
nurs
activ
bodi
weight
viabil
establish
reliabl
indic
normal
develop
design
vaccin
dart
studi
review
wolf
et
al
brief
femal
anim
strategi
nonclin
safeti
assess
vaccin
nize
week
mate
order
ensur
peak
immun
respons
critic
phase
pregnanc
eg
organogenesi
vaccin
booster
dose
administ
gestat
embryofet
period
lactat
postnat
period
evalu
potenti
direct
embryotox
effect
compon
vaccin
formul
maintain
immun
respons
throughout
remaind
gestat
adjuv
includ
vaccin
adjuvantalon
control
group
could
also
includ
similar
approach
gener
repeatdos
toxic
studi
discuss
gener
toxicolog
studi
next
gener
vaccin
particularli
vaccin
contain
immunopotenti
adjuv
question
concern
voic
regard
design
dart
studi
delin
fda
guidanc
question
discuss
workshop
nonclin
evalu
vaccin
report
particip
gener
agre
primari
object
design
current
dart
studi
perform
accord
exist
guidelin
appropri
speci
fi
c
chang
recommend
furthermor
con
fi
rmed
speci
fi
c
immunotoxicolog
endpoint
necessari
sinc
evalu
antibodi
respons
vaccin
antigen
dart
studi
adequ
assess
effect
vaccin
immun
system
treat
mother
indirectli
develop
immun
system
offspr
addit
immun
paramet
evalu
casebycas
basi
increas
concern
potenti
immunotox
also
dart
studi
would
reveal
vaccineinduc
advers
effect
either
pregnantlact
anim
embryofet
develop
develop
offspr
nonclin
studi
evalu
caus
effect
conduct
followup
studi
would
includ
broader
immunolog
evalu
eg
histochem
analysi
antibodi
deposit
evalu
lymphoid
organ
weight
histolog
hematolog
gener
qualiti
control
biolog
materi
involv
analyt
biolog
test
identifi
qualiti
attribut
ident
puriti
potenc
mass
assess
safeti
includ
steril
pyrogen
adventiti
agent
vivo
qualiti
test
conduc
support
market
product
clinic
materi
well
preclin
materi
main
goal
type
test
identifi
issu
may
arisen
manufactur
ie
introduct
adventiti
agentscontamin
chang
potenc
andor
properti
cell
substrat
biolog
start
materi
time
test
may
also
use
screen
tool
biolog
materi
may
inher
characterist
may
affect
safeti
andor
toler
eg
pyrogen
test
vaccin
candid
bacteri
compon
potenti
sourc
contamin
biotechnolog
product
includ
origin
sourc
cell
line
adventiti
introduct
manufactur
process
exampl
sourc
contamin
list
ich
usp
product
licens
countri
may
also
speci
fi
c
pharmaopoeia
eg
china
japan
brittan
manufactur
also
consult
guidelin
prior
market
vaccin
region
typic
detail
test
contain
product
licens
supersed
current
guidanc
document
unless
speci
fi
c
regulatori
approv
sought
updat
licens
question
speci
fi
c
guidanc
particular
type
vaccin
cell
substrat
stage
product
addit
guidelin
avail
tabl
guidanc
document
also
avail
regulatori
submiss
test
support
releas
product
gener
follow
current
good
manufactur
process
cgmp
guidelin
though
test
conduct
per
glp
eg
tumorigen
test
test
requir
vari
region
manufactur
market
biolog
worldwid
typic
design
assay
criteria
market
may
sati
fi
ed
singl
assay
exampl
speci
fi
cation
gener
safeti
test
list
cfr
differ
ep
therefor
one
could
design
gener
safeti
test
satisfi
market
use
greatest
number
anim
speci
fi
ed
mice
guinea
pig
weight
rang
inclus
rang
region
g
mice
g
guinea
pig
durat
region
one
longer
presum
longer
durat
would
select
speci
fi
cation
select
outsid
rang
one
market
may
necessari
gain
regulatori
approv
base
rational
reduct
anim
use
strategi
nonclin
safeti
assess
vaccin
speci
fi
c
vivo
test
includ
variou
speci
speci
less
sensit
particular
adventiti
agent
sensit
speci
alway
use
adult
suckl
mice
util
detect
adventiti
virus
adult
mice
detect
lymphocyt
choriomening
viru
lcmv
coxsackievirus
fl
avivirus
rabi
viru
suckl
mice
detect
coxsackieviru
type
b
picornavirus
poliovirus
echovirus
alphavirus
bunyavirus
includ
phlebovirus
nairovirus
arenavirus
fl
avivirus
rabi
herpesvirus
herp
simplex
viru
guinea
pig
sensit
mycobacterium
tuberculosi
adventiti
virus
includ
paramyxovirus
includ
sendai
viru
reovirus
fi
lovirus
rabbit
use
screen
simian
herp
b
viru
egg
also
util
via
variou
inject
rout
detect
herpesvirus
poxvirus
rhabdovirus
rickettsia
mycoplasma
bacteria
orthomyxovirus
fl
uenza
viru
paramyxovirus
mump
measl
parain
fl
uenza
virus
alphavirus
vesiculovirus
antibodi
product
test
hamster
rat
mice
util
detect
speci
fi
c
virus
endpoint
vari
test
includ
physic
sign
surviv
bodi
weight
bodi
temperatur
antibodi
level
andor
gross
necropsi
andor
histopatholog
evalu
tabl
altern
vivo
test
develop
exampl
vitro
altern
rabbit
pyrogen
test
includ
limulu
amebocyt
lysat
lal
monocyt
activ
test
mat
lal
assay
wellestablish
vitro
test
wide
use
detect
pyrogen
endotoxin
biolog
product
assay
util
intend
purpos
unabl
detect
nonendotoxin
pyrogen
fals
posit
result
may
obtain
vaccin
contain
bacteri
compon
therefor
rabbit
pyrogen
test
still
use
product
lal
inappropri
effort
reduc
anim
use
mat
novel
vitro
assay
develop
valid
detect
endotoxin
nonendotoxin
pyrogen
assay
involv
stimul
lymphocyt
popul
whole
blood
peripher
blood
mononuclear
cell
pbmc
reproduc
cell
line
monomac
analyt
interest
measur
cytokin
releas
b
tnfa
assay
also
list
altern
rabbit
pyrogen
test
ep
test
adventiti
agent
also
vitro
altern
vitro
test
cultur
pcr
identi
fi
cation
mycobacterium
case
accept
altern
test
guinea
pig
test
rabbit
presenc
herp
b
viru
primari
simian
cultur
may
replac
test
rabbit
kidney
cell
cultur
also
possibl
replac
vivo
potenc
test
vitro
method
design
potenc
studi
fl
exibl
gener
productspeci
fi
c
vivo
model
avail
one
may
start
anim
typic
mous
test
plan
move
vitro
model
proven
correl
vivo
data
effort
reduc
anim
use
note
howev
vitro
test
may
alway
correl
clinic
experi
due
abil
detect
chemic
chang
may
lead
function
effect
potenc
vivo
assay
design
detect
neurovirul
potenti
live
viru
vaccin
tradit
requir
use
nonhuman
primat
nhp
monkey
neurovirul
test
mnvt
type
test
remain
appropri
neurotrop
viru
strain
eg
polio
yellow
fever
workshop
jointli
organ
intern
associ
biolog
iab
ep
recommend
mnv
test
longer
requir
establish
strain
proven
safeti
record
measl
mump
rubella
varicella
fact
ep
monograph
measl
mump
rubella
varicella
requir
new
strain
virus
evalu
neurovirul
test
appropri
anim
model
conduct
preclin
develop
addit
fda
remov
requir
neurovirul
test
cfr
case
neurovirul
test
requir
exampl
inadequ
data
neurovirul
viru
novel
vaccin
develop
neurotrop
neurovirul
appar
novel
vaccin
attenu
passag
neuron
tissu
howev
novel
model
neurovirul
test
involv
use
nhp
pursu
exampl
rubin
et
al
develop
neonat
rat
model
shown
better
predict
valu
mnvt
distinguish
neurovirul
attenu
strain
mump
viru
test
system
marmoset
also
evalu
show
promis
nonanimalbas
test
method
also
consid
full
replac
anim
test
may
feasibl
complex
neurovirul
virus
may
adequ
fl
ect
strategi
nonclin
safeti
assess
vaccin
addit
vivo
test
describ
tabl
sever
vitro
test
also
detect
adventiti
virus
cell
cultur
safeti
test
human
diploid
monkey
kidney
cell
detect
varieti
adventiti
virus
includ
cytopath
virus
hemadsorpt
virus
hemagglutin
virus
use
human
diploid
cell
identi
fi
es
varieti
human
virus
herpesvirus
adenovirus
coronavirus
reovirus
alphavirus
rubella
fl
avivirus
rabi
enterovirus
certain
strain
hepat
viru
polioviru
coxsacki
b
viru
echoviru
rhinovirus
orthomyxovirus
paramyxovirus
simian
virus
simian
cytomegaloviru
use
monkey
kidney
cell
could
identifi
human
virus
enterovirus
coxsacki
b
virus
echovirus
orthomyxovirus
paramyxovirus
hsv
poxvirus
polyomavirus
rotaviru
alphavirus
rubella
fl
avivirus
rabi
virus
vesiculovirus
fi
lovirus
fl
uenza
virus
bunyavirus
includ
phlebovirus
nairovirus
arenavirus
reovirus
poliovirus
rhinovirus
adenovirus
strain
simian
virus
herp
b
viru
test
detect
adventiti
virus
includ
transmiss
electron
microscopi
tem
detect
viral
particl
cell
substrat
includ
endogen
retrovirus
revers
transcriptas
rt
assay
detect
retroviru
retrovirus
encod
contain
rt
infect
test
retrovirus
perform
casebycas
basi
pcr
southern
blot
perform
detect
speci
fi
c
virus
vitro
test
nonvir
adventiti
agent
includ
test
mycoplasma
mycobacteria
bacteri
fungal
steril
safeti
test
product
releas
includ
test
presenc
residu
cell
dna
residu
cellular
nuclear
materi
fi
nal
product
pose
potenti
risk
oncogen
andor
infect
potenti
dna
remov
digest
inactiv
lessen
risk
develop
broad
rang
novel
next
gener
vaccin
contain
synthet
andor
recombin
compon
rather
microorganismderiv
compon
clear
advantag
manufactur
process
control
perspect
continu
progress
technolog
especi
molecular
genet
methodolog
appli
discoveri
vaccin
formul
scienc
develop
welld
fi
ned
speci
fi
c
antigen
use
vaccin
enabl
product
next
gener
novel
vaccin
prevent
andor
treat
diseas
refractori
vaccin
past
scienti
fi
c
technolog
advanc
led
improv
vaccin
product
aim
elimin
potenti
virul
carcinogen
compon
reduct
impur
howev
vaccin
contain
purer
antigen
often
immunogen
therefor
requir
addit
effect
adjuv
excipi
paradox
next
gener
vaccin
de
fi
ned
better
character
tradit
vaccin
view
less
natur
also
advanc
molecular
engin
lead
use
novel
adjuv
compon
well
novel
deliveri
system
alway
parallel
full
understand
biolog
mechan
action
compon
limit
understand
mechan
action
newli
avail
vaccin
adjuv
lead
increas
concern
safeti
nevertheless
mani
recent
scienti
fi
c
regulatori
discuss
dedic
topic
seem
indic
current
recommend
appli
approach
nonclin
develop
includ
toxicolog
studi
vaccin
candid
appropri
adequ
principl
nonclin
safeti
assess
review
chapter
provid
foundat
evalu
next
gener
vaccin
